Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BG Medicine, Inc. (BGMD)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Medical - Instruments & Supplies
Address
303 Wyman Street 2451
Waltham, MA, US
Waltham, MA, US
CEO
Stephen Hall
Website
bg-medicine.com
IPO
2011-02-04
ISIN US08861T2069
Description
BG Medicine, Inc. is dedicated to the development and commercialization of diagnostic products aimed at guiding patient care for individuals in the United States afflicted with heart failure and related conditions. Its product portfolio includes the BGM Galectin-3 Test, an in vitro diagnostic solution that quantifies galectin-3 levels in blood serum or plasma using an enzyme-linked immunosorbent assay (ELISA) on a microtiter plate platform. Additionally, the company provides the CardioSCORE Test, a multi-analyte, biomarker-based blood test designed to assess the short-term risk of atherothrombotic cardiovascular events, such as myocardial infarction (heart attack) and ischemic stroke. BG Medicine maintains licensing, development, and commercialization agreements with major partners like Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc., specifically for automated versions of its galectin-3 test. Furthermore, it has forged a strategic alliance with Abbott Laboratories to jointly develop and market galectin-3 assay kits, along with their corresponding control kits and calibrators. Founded in 2000, the company was initially known as Beyond Genomics, Inc., before rebranding to BG Medicine, Inc. in October 2004. Its corporate headquarters are located in Waltham, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.5K
Beta
-44.60
Float Shares
8.31M
Free Float %
73.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +9,900.00% | +9,900.00% | +0.00% | -99.75% | -99.95% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Hold
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-115.94
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%-43.8% Q4'15: -47.7% (vs Q4'14)
-
EPS growth Medical - Instruments & Supplies: +16.3%+44.4% ★ Q4'15: +46.6% (vs Q4'14)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-334.6% Q4'15: -385.2% (vs Q4'14)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-328.5% Q4'15: -311.0% (vs Q4'14)
-
ROIC Medical - Instruments & Supplies: +6.0%— Q4'15: +103.1% (vs Q4'14)
-
Share dilution Medical - Instruments & Supplies: +0.1%+17.5% Q4'15: +30.8% (vs Q4'14)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.00× Q4'15: 0.00× (vs Q4'14)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-3.80M
OE per share TTM
-0.40
Owner's Yield
-337,307.89%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
10.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-02-04 | LUBER JEFFREY R | Director | A-Award | A | Stock option (right to buy) | 10,000 | 0.29 | 2.9K | 10,000 | — | ↗ |
| 2015-12-09 | AFEYAN NOUBAR | Director / 10% Owner | S-Sale | D | Common Stock | 2,508 | 0.56 | 1.4K | 0 | — | ↗ |
| 2015-11-18 | PAPADOPOULOS STELIOS | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.52 | 2.6K | 5,000 | — | ↗ |
| 2015-11-18 | AFEYAN NOUBAR | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 5,000 | 0.52 | 2.6K | 5,000 | — | ↗ |
| 2015-07-27 | AFEYAN NOUBAR | Director / 10% Owner | X-InTheMoney | A | Common Stock | 4,205 | 0.14 | 588.70 | 771,475 | — | ↗ |
| 2015-07-14 | Flagship Ventures 2007 General Partner LLC | 10% Owner | — | I | Series A Preferred Stock | 497,729 | 0.00 | — | 0 | — | ↗ |
| 2015-07-14 | AFEYAN NOUBAR | Director / 10% Owner | C-Conversion | A | Series A Preferred Stock | 13,553 | 0.00 | — | 13,553 | — | ↗ |
| 2014-12-04 | AFEYAN NOUBAR | Director / 10% Owner | J-Other | A | Common Stock | 164,528 | 0.00 | — | 175,718 | — | ↗ |
| 2014-12-03 | AFEYAN NOUBAR | Director / 10% Owner | X-InTheMoney | A | Common Stock | 847 | 0.02 | 16.94 | 93,400 | — | ↗ |
| 2014-06-03 | Posner Brian S | Director | A-Award | A | Stock Option (right to buy) | 4,205 | 1.00 | 4.2K | 4,205 | — | ↗ |
| 2014-06-03 | PAPADOPOULOS STELIOS | Director | A-Award | A | Stock Option (right to buy) | 4,205 | 1.00 | 4.2K | 4,205 | — | ↗ |
| 2014-06-03 | Bancel Stephane | Director | A-Award | A | Stock Option (right to buy) | 4,205 | 1.00 | 4.2K | 4,205 | — | ↗ |
| 2014-06-03 | BAINS HARRISON M JR | Director | A-Award | A | Stock Option (right to buy) | 4,205 | 1.00 | 4.2K | 4,205 | — | ↗ |
| 2014-06-03 | AFEYAN NOUBAR | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 4,205 | 1.00 | 4.2K | 4,205 | — | ↗ |
| 2013-11-01 | Bancel Stephane | Director | A-Award | A | Stock Option (right to buy) | 101,351 | 0.62 | 62.8K | 101,351 | — | ↗ |
| 2013-08-01 | Bancel Stephane | Director | A-Award | A | Stock Option (right to buy) | 52,083 | 1.20 | 62.5K | 52,083 | — | ↗ |
| 2013-06-12 | Posner Brian S | Director | A-Award | A | Stock Option (Right to Buy) | 4,205 | 1.68 | 7.1K | 4,205 | — | ↗ |
| 2013-06-12 | PAPADOPOULOS STELIOS | Director | A-Award | A | Stock Option (right to buy) | 4,205 | 1.68 | 7.1K | 4,205 | — | ↗ |
| 2013-06-12 | BAINS HARRISON M JR | Director | A-Award | A | Stock Option (right to buy) | 4,205 | 1.68 | 7.1K | 4,205 | — | ↗ |
| 2013-06-12 | AFEYAN NOUBAR | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 4,205 | 1.68 | 7.1K | 4,205 | — | ↗ |
| 2013-05-01 | Bancel Stephane | Director | A-Award | A | Stock Option (right to buy) | 39,473 | 1.61 | 63.6K | 39,473 | — | ↗ |
| 2013-01-30 | PAPADOPOULOS STELIOS | Director | P-Purchase | A | Common Stock | 250,000 | 2.00 | 500.0K | 1,187,713 | — | ↗ |
| 2013-01-30 | AFEYAN NOUBAR | Director / 10% Owner | P-Purchase | A | Common Stock | 1,050,000 | 2.00 | 2.10M | 1,764,286 | — | ↗ |
| 2012-11-19 | Posner Brian S | Director | P-Purchase | A | Common Stock | 10,000 | 1.17 | 11.7K | 20,000 | — | ↗ |
| 2012-11-15 | Bancel Stephane | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 1.26 | 126.0K | 123,167 | — | ↗ |
| 2012-09-13 | Bancel Stephane | Director / Officer | P-Purchase | A | Common Stock | 1,381 | 3.70 | 5.1K | 23,167 | — | ↗ |
| 2012-08-21 | AFEYAN NOUBAR | Director / 10% Owner | J-Other | D | Common Stock | 298,137 | 0.00 | — | 0 | — | ↗ |
| 2012-08-20 | AFEYAN NOUBAR | Director / 10% Owner | S-Sale | D | Common Stock | 23 | 5.83 | 134.09 | 285,339 | — | ↗ |
| 2012-06-11 | PAPADOPOULOS STELIOS | Director | A-Award | A | Stock Option (right to buy) | 4,205 | 5.69 | 23.9K | 4,205 | — | ↗ |
| 2012-06-11 | BAINS HARRISON M JR | Director | A-Award | A | Stock Option (right to buy) | 4,205 | 5.69 | 23.9K | 4,205 | — | ↗ |
| 2012-06-11 | AFEYAN NOUBAR | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 4,205 | 5.69 | 23.9K | 4,205 | — | ↗ |
| 2012-05-23 | AFEYAN NOUBAR | Director / 10% Owner | J-Other | D | Common Stock | 130,867 | 0.00 | — | 0 | — | ↗ |
| 2012-05-22 | Posner Brian S | Director | P-Purchase | A | Common Stock | 10,000 | 4.04 | 40.4K | 10,000 | — | ↗ |
| 2012-05-21 | AFEYAN NOUBAR | Director / 10% Owner | X-InTheMoney | A | Common Stock | 7,001 | 0.02 | 140.02 | 130,903 | — | ↗ |
| 2012-05-17 | Bancel Stephane | Director / Officer | P-Purchase | A | Common Stock | 5,008 | 3.84 | 19.2K | 21,786 | — | ↗ |
| 2012-04-17 | van der Meer Pieter | 10% Owner | S-Sale | D | Common Stock | 200,000 | 6.60 | 1.32M | 1,635,432 | — | ↗ |
| 2012-02-27 | PAPADOPOULOS STELIOS | Director | A-Award | A | Stock Option (right to buy) | 4,205 | 7.78 | 32.7K | 4,205 | — | ↗ |
| 2012-02-27 | Bancel Stephane | Director / Officer | A-Award | A | Stock Option (right to buy) | 4,205 | 7.78 | 32.7K | 4,205 | — | ↗ |
| 2012-02-27 | BAINS HARRISON M JR | Director | A-Award | A | Stock Option (right to buy) | 4,205 | 7.78 | 32.7K | 4,205 | — | ↗ |
| 2012-02-27 | AFEYAN NOUBAR | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 4,205 | 7.78 | 32.7K | 4,205 | — | ↗ |
| 2012-02-22 | Bancel Stephane | Director / Officer | P-Purchase | A | Common Stock | 2,778 | 0.00 | — | 16,778 | — | ↗ |
| 2012-02-13 | Posner Brian S | Director | A-Award | A | Stock Option (right to buy) | 8,410 | 8.27 | 69.6K | 8,410 | — | ↗ |
| 2011-11-29 | PAPADOPOULOS STELIOS | Director | X-InTheMoney | A | Common Stock | 1,833 | 0.03 | 54.99 | 907,831 | — | ↗ |
| 2011-11-09 | PAPADOPOULOS STELIOS | Director | M-Exempt | A | Common Stock | 336,441 | 0.90 | 302.8K | 787,175 | — | ↗ |
| 2011-09-19 | AFEYAN NOUBAR | Director / 10% Owner | J-Other | D | Common Stock | 193,133 | 0.00 | — | 104,928 | — | ↗ |
| 2011-09-12 | Bancel Stephane | Director / Officer | P-Purchase | A | Common Stock | 6,000 | 3.63 | 21.8K | 14,000 | — | ↗ |
| 2011-09-09 | Bancel Stephane | Director / Officer | P-Purchase | A | Common Stock | 4,000 | 4.30 | 17.2K | 8,000 | — | ↗ |
| 2011-09-08 | Bancel Stephane | Director / Officer | P-Purchase | A | Common Stock | 4,000 | 4.40 | 17.6K | 4,000 | — | ↗ |
| 2011-07-25 | Bancel Stephane | Director / Officer | A-Award | A | Stock Option (right to buy) | 235,390 | 8.11 | 1.91M | 235,390 | — | ↗ |
| 2011-02-09 | van der Meer Pieter | Director / 10% Owner | C-Conversion | D | Series D Preferred Stock | 366,809 | 0.00 | — | 0 | — | ↗ |
| 2011-02-09 | PAPADOPOULOS STELIOS | Director | C-Conversion | D | Series D Preferred Stock | 80,393 | 0.00 | — | 0 | — | ↗ |
| 2011-02-09 | AFEYAN NOUBAR | Director / 10% Owner | C-Conversion | A | Common Stock | 59,386 | 0.00 | — | 59,386 | — | ↗ |
| 2011-02-03 | van der Meer Pieter | Director / 10% Owner | — | I | Warrant to Purchase Common Stock | 23,080 | 0.02 | 461.60 | 0 | — | ↗ |
| 2011-02-03 | PAPADOPOULOS STELIOS | Director | — | D | Stock Option (right to buy) | 336,441 | 0.90 | 302.8K | 0 | — | ↗ |
| 2011-02-03 | Bancel Stephane | Director | — | D | Stock Option (right to buy) | 32,410 | 10.67 | 345.8K | 0 | — | ↗ |
| 2011-02-03 | BAINS HARRISON M JR | Director | — | D | Stock Option (right to buy) | 23,999 | 7.50 | 180.0K | 0 | — | ↗ |
| 2011-02-03 | AFEYAN NOUBAR | Director / 10% Owner | — | I | Series D Preferred Stock | 469,218 | 0.00 | — | 0 | — | ↗ |
| 2010-11-04 | van der Meer Pieter | Director / 10% Owner | P-Purchase | A | Warrant to Purchase Common Stock | 23,080 | 0.02 | 461.60 | 23,080 | — | ↗ |
| 2010-11-04 | PAPADOPOULOS STELIOS | Director | P-Purchase | A | Warrant to Purchase Common Stock | 5,773 | 0.02 | 115.46 | 5,773 | — | ↗ |
| 2010-11-04 | AFEYAN NOUBAR | Director / 10% Owner | P-Purchase | A | Convertible Promissory Notes | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-10.3K
Shares Outstanding
11.37M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephen Hall | Chief Financial Officer, Executive Vice President & Treasurer | 351.0K | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BGMD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
